Evidence map›Paper›PMID 33523236›Full record

ArticleJournal of the National Cancer Institute2021

Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma.

Nathanael R Fillmore, Clark DuMontier, Cenk Yildirim, Jennifer La, Mara M Epstein, David Cheng, Diana Cirstea, Sarvari Yellapragada, Gregory A Abel, J Michael Gaziano and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Nathanael R FillmoreVA Boston CSP Center, Boston, MA, USA.ORCID 0000-0002-8058-3423
Clark DuMontierHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-2582-7816
Cenk YildirimVA Boston CSP Center, Boston, MA, USA.
Jennifer LaVA Boston CSP Center, Boston, MA, USA.
Mara M EpsteinThe Meyers Primary Care Institute and the Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
David ChengMassachusetts General Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Diana CirsteaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5719-581X
Sarvari YellapragadaMichael E Debakey VA Medical Center and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Gregory A AbelDivisions of Hematologic Malignancy and Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1100-2813
J Michael GazianoMassachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Boston, MA, USA.
Nhan DoVA Boston CSP Center, Boston, MA, USA.
Mary BrophyVA Boston CSP Center, Boston, MA, USA.
Dae H KimHarvard Medical School, Boston, MA, USA.ORCID 0000-0001-7290-6838
Nikhil C MunshiVA Boston Healthcare System, Boston, MA, USA.
Jane A DriverHarvard Medical School, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USBoston VA Research Institute · USVA Boston Healthcare System · USBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · USMichael E. DeBakey VA Medical Center · USUniversity of Massachusetts Chan Medical School · US

Funding

Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0M
Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI RICHARD YOUNG · 2011 to 2026
$32.5M
Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
Translational Researchin Aging Trainnig ProgramT32AG023480 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2004 to 2024
$7.6M
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–
Improving Analysis of Endogenous Multimodal Treatments for Use in Geriatrics Health Outcomes StudiesI01HX002237 · VA · VA BOSTON HEALTH CARE SYSTEM · PI GARRIDO, MELISSA M · 2018 to 2021
–
BLRD VA I01 BX001584CSRD VA IK2 CX002218NCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707NIA NIH HHS R33 AG057806NIA NIH HHS T32 AG023480
6 · The paper itself

Abstract

backgroundTraditional count-based measures of comorbidity are unlikely to capture the complexity of multiple chronic conditions (multimorbidity) in older adults with cancer. We aimed to define patterns of multimorbidity and their impact in older United States veterans with multiple myeloma (MM).

methodsWe measured 66 chronic conditions in 5076 veterans aged 65 years and older newly treated for MM in the national Veterans Affairs health-care system from 2004 to 2017. Latent class analysis was used to identify patterns of multimorbidity among these conditions. These patterns were then assessed for their association with overall survival, our primary outcome. Secondary outcomes included emergency department visits and hospitalizations.

resultsFive patterns of multimorbidity emerged from the latent class analysis, and survival varied across these patterns (log-rank 2-sided P < .001). Older veterans with cardiovascular and metabolic disease (30.9%, hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 1.21 to 1.45), psychiatric and substance use disorders (9.7%, HR = 1.58, 95% CI = 1.39 to 1.79), chronic lung disease (15.9%, HR = 1.69, 95% CI = 1.53 to 1.87), and multisystem impairment (13.8%, HR = 2.25, 95% CI = 2.03 to 2.50) had higher mortality compared with veterans with minimal comorbidity (29.7%, reference). Associations with mortality were maintained after adjustment for sociodemographic variables, measures of disease risk, and the count-based Charlson Comorbidity Index. Multimorbidity patterns were also associated with emergency department visits and hospitalizations.

conclusionsOur findings demonstrate the need to move beyond count-based measures of comorbidity and consider cancer in the context of multiple chronic conditions.

Indexed as

Multiple Chronic ConditionsMultiple MyelomaVeteransAgedComorbidityHumansMultimorbidityUnited States

Identifiers

PMID33523236
PMCPMC8328982
OpenAlexW3126778740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.